Off-label prescribing lawsuits target pharmaceutical companies that promote or incentivize doctors to prescribe medications for uses not approved by the FDA, often without adequate safety data or disclosure to patients. These lawsuits have become one of the most significant enforcement mechanisms in healthcare law, resulting in billions of dollars in settlements and reshaping how manufacturers can market drugs. The legal foundation rests primarily on the Anti-Kickback Statute and the False Claims Act, which prohibit companies from offering financial incentives to prescribers and from making false claims to insurance companies or government programs that cover off-label use. The scope of off-label prescribing is staggering.
Recent data shows that approximately 1 in 5 prescriptions written in the United States are off-label, with psychiatry seeing even higher rates at 31% of all prescriptions. The practice itself is legal when doctors make independent clinical judgments, but when pharmaceutical companies actively promote off-label uses through speaker programs, meals, consulting fees, or other inducements, it crosses into illegal territory. A concrete example is Pfizer’s subsidiary Biohaven, which in January 2025 paid $60 million to resolve allegations that it illegally paid physicians speaker honoraria and provided meals specifically to promote off-label use of a migraine medication. Recent years have brought a wave of major settlements and ongoing litigation that demonstrates both the aggressive enforcement of these laws and the significant financial consequences for pharmaceutical companies. The cases span from established drugs being promoted for unapproved conditions to newer medications like GLP-1 receptor agonists, where off-label prescribing has generated billions in additional revenue while raising serious safety concerns.
Table of Contents
- What Constitutes Off-Label Prescribing and When Does It Become Illegal?
- Recent Major Settlements and the Pattern of Pharmaceutical Liability
- The GLP-1 Litigation Wave—Off-Label Use at Scale
- How Off-Label Marketing Schemes Operate in Practice
- The Problem of Injury Causation in Off-Label Litigation
- Government vs. Private Off-Label Litigation—Different Standards and Recovery
- The Future of Off-Label Litigation and Enforcement Trends
- Conclusion
What Constitutes Off-Label Prescribing and When Does It Become Illegal?
Off-label prescribing occurs when a doctor prescribes an FDA-approved medication for a use, dosage, age group, or patient population that the FDA has not explicitly approved. Once a drug is approved for any indication, physicians have the legal right to prescribe it off-label based on their clinical judgment and medical literature. This practice is entirely lawful and sometimes necessary when no approved alternatives exist. However, pharmaceutical manufacturers cannot legally promote, market, or incentivize off-label prescribing.
The line between legal clinical practice and illegal pharmaceutical promotion is where off-label prescribing litigation arises. The distinction matters enormously for liability. A company that allows its sales representatives to distribute off-label study data to physicians for educational purposes faces far less legal risk than a company that pays physicians bonuses tied to off-label prescription volume or sponsors luxurious speaker events designed to influence prescribing patterns rather than educate. Eli Lilly faced this exact scenario with its antipsychotic Zyprexa, for which the company aggressively promoted off-label use in elderly dementia patients—a population with increased mortality risk. When Eli Lilly settled for up to $800 million in 2009, it was because the company had systematized off-label promotion through its sales force, not because off-label prescribing itself was the problem.
Recent Major Settlements and the Pattern of Pharmaceutical Liability
The 2025 settlements mark an escalation in enforcement against off-label promotion schemes. Gilead Sciences agreed to pay $202 million in April 2025 to resolve nationwide allegations of a kickback scheme involving HIV medications. Simultaneously, Pfizer’s Biohaven subsidiary paid $60 million for illegal speaker honoraria and meal programs promoting off-label migraine medication use. These settlements underscore that pharmaceutical companies continue to deploy the same prohibited tactics despite decades of enforcement history, suggesting that the cost of settlement remains lower than the revenue generated from off-label promotion. Historical benchmarks reveal the scale at which this litigation operates.
GlaxoSmithKline paid $3 billion in 2012—the largest pharmaceutical settlement in U.S. history—for deceptive marketing, off-label promotion, and kickback schemes across multiple drugs. Johnson & Johnson’s Janssen subsidiary paid $1.391 billion for off-label marketing and kickbacks of Risperdal and Invega. Pfizer has paid $2.3 billion in total fines, including $1.3 billion in criminal penalties alone. These are not minor business adjustments; they represent fundamental failures in corporate compliance. A critical limitation, however, is that settlements typically resolve only the government’s claims and may not fully compensate injured patients or deter future misconduct.
The GLP-1 Litigation Wave—Off-Label Use at Scale
The current litigation landscape is dominated by consolidated federal multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania involving thousands of lawsuits against Novo Nordisk and Eli Lilly over their GLP-1 receptor agonists, including Ozempic and Wegovy. Plaintiffs allege that aggressive off-label prescribing and promotion of these weight-loss drugs has caused severe gastrointestinal injuries and complications in patients who were prescribed them without FDA approval for their specific conditions. This litigation represents one of the largest pharmaceutical disputes currently pending in federal court, with potential damages that could dwarf individual drug settlements. The financial stakes underscore why companies engage in off-label promotion despite legal risks.
Off-label GLP-1 use generated billions in additional revenue for manufacturers beyond what their FDA-approved indications would have generated. Novo Nordisk’s Ozempic was approved for type 2 diabetes, yet celebrities, influencers, and millions of patients have used it off-label for weight loss—a market that expanded exponentially before FDA approval of Wegovy for weight management. mass settlements in the GLP-1 litigation are unlikely before late 2027, with bellwether trials scheduled for 2026 to determine liability and compensation values. This timeline matters for injured patients who will continue bearing medical expenses and complications during years of litigation.
How Off-Label Marketing Schemes Operate in Practice
Pharmaceutical companies employ several mechanisms to promote off-label use while maintaining legal cover. Speaker programs are among the most common: a company pays physicians to give talks about a drug, ostensibly for education, but structures the program to target specific prescriber audiences and often discusses off-label applications. Consulting fees and advisory board positions provide another pathway, allowing companies to compensate high-prescribing physicians while creating an appearance of professional engagement. Meals and entertainment at medical conferences create informal settings where sales representatives can discuss off-label applications more freely than in formal marketing materials.
The comparison between legal and illegal off-label promotion reveals the sophistication of violation schemes. A pharmaceutical company can legally distribute peer-reviewed medical literature about off-label uses to prescribers who request it. The same company cannot distribute that literature through sales representatives with quotas tied to off-label prescriptions, or bundle the literature with meals and entertainment designed to build relationships. Warner-Lambert’s 1994 settlement of $430 million for illegal Neurontin promotion established the template: the company paid sales representatives bonuses for off-label volume, sponsored continuing medical education events that promoted off-label uses, and provided free drug samples to encourage off-label experimentation. Modern settlement data shows these tactics persist unchanged.
The Problem of Injury Causation in Off-Label Litigation
One of the most significant limitations in off-label prescribing lawsuits is proving injury causation—establishing that the medication actually harmed the plaintiff and that the pharmaceutical company’s marketing directly caused the physician to prescribe it for an unapproved use. In many settlements, the government claims false statements to federal programs, which requires only proof that claims were submitted; injury to individual patients is secondary. When private plaintiffs sue for personal injury from off-label prescriptions, courts require them to prove not only that the company illegally promoted the drug, but that their specific physician prescribed it based on that illegal promotion rather than independent clinical judgment. This causation gap creates a warning for patients considering joining off-label litigation.
Even if a company paid physicians to promote off-label use, a plaintiff must show that their physician either received direct payments or was influenced by the promotional scheme. If a physician discovered the off-label use through medical literature, a conference presentation by an independent researcher, or simply clinical experience with the drug, the company’s illegal promotion becomes harder to prove as the cause of that specific prescription decision. Pediatric off-label prescribing presents additional complexity: although 62% of U.S. pediatric office visits included off-label prescribing between 2001 and 2004, many of these were clinically necessary due to lack of approved pediatric formulations, complicating liability analysis.
Government vs. Private Off-Label Litigation—Different Standards and Recovery
Off-label prescribing lawsuits divide into two categories with distinct legal standards and recovery mechanisms. Government enforcement through the Department of Justice, state attorneys general, and the False Claims Act focuses on claims submitted to federal healthcare programs (Medicare, Medicaid, Veterans Affairs). These cases require proof of a false claim submitted to a government program and knowledge of falsity, but do not require individual patient injury. Most of the major settlements discussed—Gilead’s $202 million, Biohaven’s $60 million, GSK’s $3 billion—resolved primarily government claims under the False Claims Act.
Government settlements typically allocate a portion of recovery through qui tam relators (whistleblowers), but the bulk goes to federal and state treasuries. Private litigation involves injured patients suing manufacturers for damages under product liability, fraud, and consumer protection laws. These cases are more difficult and slower to resolve because they require proving individual injury and causation. However, they offer the potential for far larger individual recoveries when successful. The difference matters significantly for patients deciding whether to join class actions or mass tort settlements: government recovery tends toward faster settlement with lower individual payouts, while private injury litigation requires longer timelines but can produce higher compensation per claimant when liability is established.
The Future of Off-Label Litigation and Enforcement Trends
The volume and scale of off-label prescribing litigation shows no signs of declining. The Food and Drug Administration continues aggressive enforcement, and state attorneys general have positioned off-label enforcement as a priority area. The GLP-1 MDL will likely produce significant settlements that set precedent for weight-loss and metabolic drug litigation.
Simultaneously, newer classes of medications—particularly biologics, immunotherapies, and AI-driven treatments—will create novel off-label marketing challenges that existing settlement frameworks may not adequately address. One forward-looking insight is the increasing sophistication of digital marketing enforcement. Pharmaceutical companies now engage with patients through social media, influencer partnerships, and patient advocacy organizations, creating new pathways for off-label promotion that regulators are still developing tools to monitor and prosecute. As these mechanisms evolve, litigation will follow, and patients should expect off-label prescribing lawsuits to remain a central feature of pharmaceutical accountability in American healthcare.
Conclusion
Off-label prescribing lawsuits represent the primary enforcement mechanism for policing pharmaceutical marketing practices and preventing companies from paying physicians to prescribe unapproved uses of medications. Recent 2025 settlements against Gilead Sciences ($202 million) and Pfizer’s Biohaven ($60 million) demonstrate that enforcement is accelerating despite decades of prior major settlements. The ongoing GLP-1 litigation, involving thousands of plaintiffs alleging severe gastrointestinal injuries from off-label weight-loss drug use, shows that off-label promotion remains widespread and generates billions in additional revenue for manufacturers.
If you believe you were harmed by a medication prescribed off-label as a result of unlawful pharmaceutical promotion, you may have grounds for legal recovery through a class action settlement or mass tort claim. Consulting with an experienced class action attorney can help you understand whether you qualify for recovery, what settlement processes are available, and what timeline to expect for resolution. Government enforcement through the False Claims Act will likely continue generating major settlements, but individual patients pursuing injury claims should prepare for longer litigation timelines and higher evidentiary burdens.